Member Info for MarketIntel

- Acumen expects topline results from ALTITUDE-AD Phase 2 study of sabirnetug for early Alzheimer’s disease in late 2026.

- Cash position of $128.4 million as of March 31, 2026, expected to support operations into early 2027.

- Plans to license two compounds from JCR Pharmaceuticals collaboration in Q2 2026.

- R&D expenses decreased to $16.5 million in Q1 2026 from $25.3 million in Q1 2025.

- Targeting mid-2027 IND filing for lead clinical candidate in EBD program.

https://briefglance.com/companies/acumen-pharmaceuticals-inc/pulses/16479

* Alcoa will invest $65M to expand its Mosjøen smelter in Norway, adding recycled aluminum capabilities.

* The upgrade will increase production capacity by up to 75,000 metric tons and introduce a new open mold foundry casting line.

* Project completion is scheduled for phases throughout 2028.

* Since 2020, Alcoa has invested approximately $180M in sustaining and return-seeking capital projects at the smelter.

https://briefglance.com/companies/alcoa-corporation/pulses/15987